China's $184B in AI VC, 86% of Made in China 2025 targets met, R&D spending surpassing the US. The real driver is commercialisation at scale, not government funding.
UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results